Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

Author: Benzinga Newsdesk | May 03, 2024 11:22am
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $65 price target.

Posted In: GPCR